You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

CLINICAL TRIALS PROFILE FOR AZELAIC ACID


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for AZELAIC ACID

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT01025635 ↗ Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea Completed Bayer Phase 2 2009-12-01 This study will investigate the safety and efficacy of a new formulation of an existing medication for the treatment of papulopustular rosacea. The study will test the active ingredient plus foam against foam alone.
New Formulation NCT01025635 ↗ Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea Completed LEO Pharma Phase 2 2009-12-01 This study will investigate the safety and efficacy of a new formulation of an existing medication for the treatment of papulopustular rosacea. The study will test the active ingredient plus foam against foam alone.
New Dosage NCT02058628 ↗ Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris Completed GlaxoSmithKline Phase 4 2014-02-21 This is a randomized, comparator-controlled, single-blind, parallel-group study. The current study proposes to compare a fixed-dose combination product containing 3% benzoyl peroxide (BPO) and 1% clindamycin against a cream containing 20% azelaic acid for the treatment of facial acne vulgaris. The results of the study will enable a better assessment of the safety and efficacy of the new dose regime (BPO 3% + clindamycin 1%) in comparison to a well established treatment. Based on the data more evidence based recommendations will be possible to improve the treatment of subjects with acne vulgaris. A total of 220 subjects will be enrolled and will have 5 study visits (Day 1, Weeks 2, 4, 8 and 12). The duration of the study will be over 12 weeks.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for AZELAIC ACID

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00031096 ↗ Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne Completed Bayer Phase 3 2002-01-01 Comparison of efficacy and safety of Azelaic Acid 15% gel with its vehicle in male and female patients with mild to moderate acne. Qualified subjects will apply the gel to their face twice a day for a period of 12 weeks. Subjects will be required to return to the doctor's office for up to 5 visits.
NCT00031096 ↗ Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne Completed LEO Pharma Phase 3 2002-01-01 Comparison of efficacy and safety of Azelaic Acid 15% gel with its vehicle in male and female patients with mild to moderate acne. Qualified subjects will apply the gel to their face twice a day for a period of 12 weeks. Subjects will be required to return to the doctor's office for up to 5 visits.
NCT00395226 ↗ Zinc Sulfate in the Treatment of Rosacea: A Randomized, Controlled Trial Terminated Essentia Health N/A 2006-07-01 Rosacea is a common chronic dermatological condition, characterized by recurrent or persistent redness, permanent dilation of small blood vessel causing small red lesions, and papules/pustules. The signs of rosacea are usually confined to the face, but may appear on the neck, scalp or trunk. Opthalmologic findings are also common. Rosacea is usually described as being most common in fair skinned women over 40. The purpose of the study is to determine whether oral Zinc Sulfate treatment is an effective treatment for facial rosacea.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for AZELAIC ACID

Condition Name

Condition Name for AZELAIC ACID
Intervention Trials
Rosacea 9
Acne Vulgaris 8
Papulopustular Rosacea 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for AZELAIC ACID
Intervention Trials
Rosacea 18
Acne Vulgaris 8
Melanosis 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for AZELAIC ACID

Trials by Country

Trials by Country for AZELAIC ACID
Location Trials
United States 158
Germany 12
Canada 11
Egypt 2
Pakistan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for AZELAIC ACID
Location Trials
Texas 11
North Carolina 10
Florida 7
Tennessee 6
Kentucky 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for AZELAIC ACID

Clinical Trial Phase

Clinical Trial Phase for AZELAIC ACID
Clinical Trial Phase Trials
Phase 4 14
Phase 3 8
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for AZELAIC ACID
Clinical Trial Phase Trials
Completed 27
Not yet recruiting 4
Unknown status 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for AZELAIC ACID

Sponsor Name

Sponsor Name for AZELAIC ACID
Sponsor Trials
Bayer 24
LEO Pharma 11
Assiut University 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for AZELAIC ACID
Sponsor Trials
Industry 51
Other 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.